ACT up +4.89% percent Today $ACT High is at 264.00
Post# of 91
Posted On: 11/18/2014 10:34:42 AM
ACT up +4.89% percent Today $ACT High is at 264.00 and the Low 249.86 with current volume of 3,840,428.
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.29 (+12.35), PFE: 30.39 (+0.07), TEVA: 57.50 (+0.26)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 1 min ago
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.40 (+12.46)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), VRX: 142.47 (+5.74), V: 250.41 (+0.61), ALXN: 190.00 (+3.22), CTSH: 53.00 (-0.06), MA: 83.58 (+0.38), ADS: 282.20 (+1.32)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), AMAG: 35.84 (+1.08), BMY: 58.76 (+0.33)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 28.29 (-2.54), DHX: 11.38 (+0.12), ACT: 260.43 (+12.49), OME: 12.60 (-2.38), CLVS: 53.47 (+0.14), AVB: 157.72 (-0.44), PF: 32.50 (-1.22), RMTI: 10.24 (-0.34), GLW: 20.47 (+0.11), FOLD: 6.35 (-0.35)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.15 (+2.95), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), MRK: 59.63 (+0.17), VRX.TO: 160.18 (+5.78)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), SAFM: 87.09 (+2.16), PPC: 31.27 (+0.33), MIK: 21.76 (+0.11), TSN: 42.79 (-0.24)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 328.74 (+5.69), HAS: 55.99 (-0.38), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), AGN: 212.15 (+2.95), LNKD: 223.87 (+0.59), BHI: 66.13 (+0.90), CRM: 63.20 (+0.69)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), BHI: 66.13 (+0.90), Z: 120.50 (+2.64)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.15 (+2.95), HAS: 55.99 (-0.38), AMZN: 328.82 (+5.77), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), CRM: 63.21 (+0.70), BHI: 66.13 (+0.90)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), VRX: 142.47 (+5.74)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), PG: 87.79 (-0.05), MAR: 76.89 (-0.28), HOT: 77.44 (+0.59)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.45 (-0.78), AGN: 212.06 (+2.86), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.06 (+2.86), HAS: 55.97 (-0.40), ACT: 260.24 (+12.30), HAL: 49.96 (+0.73), DWA: 22.31 (unch), BHI: 66.12 (+0.89)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.05 (+2.85), ACT: 260.24 (+12.30)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.05 (+2.85), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 260.25 (+12.31), VRX: 141.71 (+4.98)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.13 (+2.93), ACT: 260.25 (+12.31), VRX: 141.71 (+4.98), VRX.TO: 160.18 (+5.78)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST
AGN: 212.03 (+2.83), ACT: 260.29 (+12.35)
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.29 (+12.35), PFE: 30.39 (+0.07), TEVA: 57.50 (+0.26)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 1 min ago
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.40 (+12.46)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), VRX: 142.47 (+5.74), V: 250.41 (+0.61), ALXN: 190.00 (+3.22), CTSH: 53.00 (-0.06), MA: 83.58 (+0.38), ADS: 282.20 (+1.32)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), AMAG: 35.84 (+1.08), BMY: 58.76 (+0.33)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 28.29 (-2.54), DHX: 11.38 (+0.12), ACT: 260.43 (+12.49), OME: 12.60 (-2.38), CLVS: 53.47 (+0.14), AVB: 157.72 (-0.44), PF: 32.50 (-1.22), RMTI: 10.24 (-0.34), GLW: 20.47 (+0.11), FOLD: 6.35 (-0.35)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.15 (+2.95), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), MRK: 59.63 (+0.17), VRX.TO: 160.18 (+5.78)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), SAFM: 87.09 (+2.16), PPC: 31.27 (+0.33), MIK: 21.76 (+0.11), TSN: 42.79 (-0.24)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 328.74 (+5.69), HAS: 55.99 (-0.38), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), AGN: 212.15 (+2.95), LNKD: 223.87 (+0.59), BHI: 66.13 (+0.90), CRM: 63.20 (+0.69)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), BHI: 66.13 (+0.90), Z: 120.50 (+2.64)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.15 (+2.95), HAS: 55.99 (-0.38), AMZN: 328.82 (+5.77), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), CRM: 63.21 (+0.70), BHI: 66.13 (+0.90)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), VRX: 142.47 (+5.74)
Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), PG: 87.79 (-0.05), MAR: 76.89 (-0.28), HOT: 77.44 (+0.59)
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.45 (-0.78), AGN: 212.06 (+2.86), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)
Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.06 (+2.86), HAS: 55.97 (-0.40), ACT: 260.24 (+12.30), HAL: 49.96 (+0.73), DWA: 22.31 (unch), BHI: 66.12 (+0.89)
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.05 (+2.85), ACT: 260.24 (+12.30)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.05 (+2.85), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST
ACT: 260.25 (+12.31), VRX: 141.71 (+4.98)
Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.13 (+2.93), ACT: 260.25 (+12.31), VRX: 141.71 (+4.98), VRX.TO: 160.18 (+5.78)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST
AGN: 212.03 (+2.83), ACT: 260.29 (+12.35)
(0)
(0)Allergan plc (AGN) Stock Research Links
Scroll down for more posts ▼